Home › Marginal Zone Lymphoma › Florida
Marginal Zone Lymphoma clinical trials in Florida
15 studies for Marginal Zone Lymphoma are looking for participants at sites in Florida.
Cities in Florida
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- University of Miami, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Boca Raton Clinical Research (BRCR) Global, Plantation
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06149286Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- University of Miami, Miami
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05700149Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- University of Miami, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2025 · NCT06796998A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.